Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Inventory: 2022-2025

Historic Inventory for Arcutis Biotherapeutics (ARQT) over the last 3 years, with Sep 2025 value amounting to $22.4 million.

  • Arcutis Biotherapeutics' Inventory rose 59.96% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year increase of 59.96%. This contributed to the annual value of $14.5 million for FY2024, which is 10.60% up from last year.
  • Arcutis Biotherapeutics' Inventory amounted to $22.4 million in Q3 2025, which was up 37.34% from $16.3 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Inventory ranged from a high of $22.4 million in Q3 2025 and a low of $4.3 million during Q3 2022.
  • For the 3-year period, Arcutis Biotherapeutics' Inventory averaged around $14.3 million, with its median value being $13.9 million (2023).
  • Data for Arcutis Biotherapeutics' Inventory shows a peak YoY spiked of 223.03% (in 2023) over the last 5 years.
  • Over the past 4 years, Arcutis Biotherapeutics' Inventory (Quarterly) stood at $7.5 million in 2022, then skyrocketed by 74.79% to $13.1 million in 2023, then climbed by 10.60% to $14.5 million in 2024, then spiked by 59.96% to $22.4 million in 2025.
  • Its Inventory stands at $22.4 million for Q3 2025, versus $16.3 million for Q2 2025 and $16.6 million for Q1 2025.